EHA 2021 | The evolving treatment landscape for multiple myeloma
Amrita Krishnan
• 14 Jun 2021
Amrita Krishnan, MD, City of Hope, Duarte, CA, gives a brief overview of the treatment landscape for multiple myeloma, highlighting recent updates including the approval of a BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy, as well as the approvals of melflufen and a BCMA-targeting antibody-drug conjugate. Dr Krishnan also comments on unmet needs in multiple myeloma and how the landscape is moving towards immunotherapies. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Amrita Krishnan, MD, has participated in consultancy work for GSK, Pfizer, Sanofi, BMS and Oncopeptides; and has participated in a speakers bureau with GSK, Amgen, BMS, Takeda and SAB Sutro.
